Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Dr Reddy's is the second largest pharmaceutical manufacturer in India, behind Ranbaxy. The company sells APIs, branded drugs and generics. Most of its branded drugs are copies of drugs patented in the West, but not in India.

Aside from simvastatin, the company's current best selling product is ramipril (Altace, King Pharmaceuticals), first introduced in non-US markets in 2003. Sales of ramipril amounted to 6.5% of total company revenues in 2004. In 2005, the company faced increased competition for this product, and revenues fell.

Dr Reddy's is also represented in western Europe, Russia and Asia. In 2002, the company made its first overseas acquisitions, both in the UK, and in 2007 the company has made the UK its European HQ. In November 2005, Dr Reddy's announced it had signed a definitive agreement to acquire Roche's API business in Cuernavaca, Mexico. In March 2006, Dr Reddy's completed its purchase of the German generic pharmaceutical firm, betapharm, from 3i, in a deal worth 480 million euros in cash.